Tempest Therapeutics
OverviewSuggest Edit
Tempest Therapeutics is a development-stage biotechnology company advancing small molecules that modulate anti-tumor immunity pathways. The Company has a balanced and deep pipeline consisting of first-in-class and potential best-in-class small molecule therapeutics that modulate distinct immune response pathways relevant to mounting an effective anti-tumor response.
| Type | Private | |
| HQ | San Francisco, CA, US | Map |
| Website | tempesttx.com |
Recent NewsAll News
- Tempest Therapeutics to Present at the Jefferies Healthcare Conference
- Tempest Therapeutics to Present at the Solebury Trout/Credit Suisse/Cooley Private Company Showcase
- Tempest Therapeutics Announces Clinical Collaboration with Roche to Advance TPST-1120 into a Randomized Combination Study in First-line Hepatocellular Carcinoma
- Tempest Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Latest Updates
| Employees (est.) (Sept 2021) | 17 | |
| Cybersecurity rating | A | More |
Key People/Management at Tempest Therapeutics
Stephen Brady
Sam Whiting
Tom Dubensky
Chan Whiting
Geoff Nichol
Anne Moon
Tempest Therapeutics Office Locations
Tempest Therapeutics Financials and Metrics
Summary Metrics
Tempest Therapeutics total Funding | $70 m |
Tempest Therapeutics latest funding size | $70 m |
Time since last funding | 3 years ago |
Tempest Therapeutics investors | Versant Ventures, Foresite Capital, F-Prime Capital Partners, Eight Roads Ventures, Lilly Asia Ventures, Quan Capital |
Tempest Therapeutics Cybersecurity Score
Tempest Therapeutics Online and Social Media Presence
Tempest Therapeutics's Trends
Tempest Therapeutics News and Updates
Tempest Therapeutics to Present at the Jefferies Healthcare Conference
Tempest Therapeutics to Present at the Solebury Trout/Credit Suisse/Cooley Private Company Showcase
Tempest Therapeutics Announces Clinical Collaboration with Roche to Advance TPST-1120 into a Randomized Combination Study in First-line Hepatocellular Carcinoma
Tempest Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Tempest Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Tempest Therapeutics Frequently Asked Questions
Who are Tempest Therapeutics key executives?
Tempest Therapeutics's key executives are Stephen Brady, Sam Whiting and Tom Dubensky.
How many employees does Tempest Therapeutics have?
Tempest Therapeutics has 17 employees.
Who are Tempest Therapeutics competitors?
Competitors of Tempest Therapeutics include Leinco Technologies, Riverside Clinical Research and Lineage Cell Therapeutics.
Where is Tempest Therapeutics headquarters?
Tempest Therapeutics headquarters is located at One Sansome Street, 1 Sansome St #3690, San Francisco, San Francisco.
Where are Tempest Therapeutics offices?
Tempest Therapeutics has offices in San Francisco and South San Francisco.
How many offices does Tempest Therapeutics have?
Tempest Therapeutics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies